RESUMEN
Bresol-a poly-herbal formulation, has been reported to be effective against bronchial asthma and allergic rhinitis in children. In vivo studies have supported the anti-histaminic and anti-anaphylactic action of bresol. However, the mechanism of action of bresol in modulation of inflammation has not been studied at the cellular and molecular level. The present study was aimed to elucidate the mechanism(s) of action of bresol at the cellular and molecular levels, using human monocyte leukemia cells. The effects of bresol on phosphodiesterase 4B (PDE4B) gene expression were analyzed using human monocytic U937 leukemia cells. The ability of bresol to stimulate cAMP formation in these cells, as well as its effects on mediators of inflammation like tumor necrosis factor-α (TNFα), nitric oxide (NO), and cycloxygenase-2 (COX-2) in lipopolysaccharide (LPS)-stimulated U937 cells, were also studied. The results here indicated that bresol exhibited potential anti-inflammatory properties by inhibiting LPS-induced PDE4B gene expression in the cells. Bresol also dose dependently activated cAMP formation, and inhibited TNFα, NO, as well as COX-2 formation in the LPS-stimulated cells. Based upon the results, we concluded that the reported anti-inflammatory activity of bresol might be attributed to its abilities to inhibit PDE4B and thus elevate cAMP levels in human monocytes. The anti-inflammatory effects of bresol might also be a result of the capacity of bresol to modulate the formation of TNFα, NO, and COX-2 in monocytes.
Asunto(s)
Fosfodiesterasas de Nucleótidos Cíclicos Tipo 4/genética , Regulación Enzimológica de la Expresión Génica/efectos de los fármacos , Mediadores de Inflamación/metabolismo , Monocitos/efectos de los fármacos , Inhibidores de Fosfodiesterasa 4/toxicidad , Preparaciones de Plantas/toxicidad , Supervivencia Celular/efectos de los fármacos , AMP Cíclico/metabolismo , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 4/metabolismo , Ciclooxigenasa 2/metabolismo , Formazáns/metabolismo , Humanos , Monocitos/metabolismo , Óxido Nítrico/metabolismo , Sales de Tetrazolio/metabolismo , Factor de Necrosis Tumoral alfa/metabolismo , Células U937RESUMEN
Oestradiol and the selective oestrogen receptor modulator (SERM) raloxifene have been shown to ameliorate collagen-induced arthritis (CIA) in rats and in mice. One aim was to investigate if raloxifene exerts its anti-arthritic and anti-osteoporotic effects during the induction or effector phase of arthritis. A second aim was to analyse if raloxifene activates the oestrogen response element (ERE) to produce its immune-modulator effects. CIA or collagen-antibody-induced arthritis (CAIA) was induced in ovariectomized DBA/1-mice. CIA was used for evaluation of treatment during the induction, and CAIA for the effector phase of arthritis and osteoporosis development. Raloxifene, oestradiol or vehicle was administered 5 days/week. The clinical disease was evaluated continuously. Bone marrow density (BMD) was analysed with peripheral quantitative computer tomography, paws were collected for histological examination, and sera were analysed for markers of bone and cartilage turnover and proinflammatory cytokines. Transgenic luciferase (Luc)-ERE mice were immunized with collagen (CII), and after 10 days injected once with raloxifene, oestradiol or vehicle before termination. Spleens were analysed for luciferase activity to measure ERE activation. Treatment with oestradiol or raloxifene during the induction phase of CIA failed to affect arthritis. Raloxifene did not hamper disease activity in CAIA, whereas oestradiol delayed the onset and ameliorated the severity. Both raloxifene and oestradiol preserved BMD in CAIA. CII-immunization increased the oestradiol-induced ERE activation in spleen, and raloxifene activated the ERE at about 25% the intensity of oestradiol. Further experiments are needed to elucidate the exact mechanisms behind this finding.
Asunto(s)
Artritis Experimental/tratamiento farmacológico , Estradiol/administración & dosificación , Osteoporosis Posmenopáusica/tratamiento farmacológico , Clorhidrato de Raloxifeno/administración & dosificación , Moduladores Selectivos de los Receptores de Estrógeno/administración & dosificación , Animales , Anticuerpos/administración & dosificación , Artritis Experimental/inducido químicamente , Artritis Experimental/complicaciones , Artritis Experimental/inmunología , Biomarcadores/sangre , Médula Ósea/patología , Colágeno/administración & dosificación , Colágeno/inmunología , Progresión de la Enfermedad , Femenino , Humanos , Inmunomodulación , Ratones , Ratones Endogámicos DBA , Ratones Transgénicos , Osteoporosis Posmenopáusica/complicaciones , Osteoporosis Posmenopáusica/etiología , Osteoporosis Posmenopáusica/inmunología , Ovariectomía , Elementos de Respuesta/genética , Transgenes/genéticaRESUMEN
The strategy of using heterogeneous stock (HS) mice has proven to be successful in fine mapping of quantitative trait loci in complex diseases. However, whether these mice can be used for arthritis, encephalomyelitis and autoimmune phenotypes has not been addressed. Here, we screened the Northport HS mice for arthritis phenotypes using three different models: collagen-induced arthritis (CIA), using rat, bovine or chicken collagen type II (CII); recombinant human glucose-6-phosphate isomerase (G6PI)-induced arthritis; and collagen antibody-induced arthritis (CAIA). Irrespective of the origin of collagen, we found HS mice to be fairly resistant to CIA and G6PI-induced arthritis, despite the development of antibodies against the respective antigens. On the other hand, HS mice were found to be susceptible for CAIA. Similarly, these mice developed encephalomyelitis (EAE) induced either with mouse or rat spinal cord homogenate (SCH), or with recombinant rat myelin oligodendrocyte glycoprotein, with elevated antibody levels against CNS proteins. Accordingly, we conclude that the use of HS mice for fine mapping and positional cloning of gene(s) involved in CAIA and EAE is possible, but not for collagen- and G6PI-induced arthritis.
Asunto(s)
Artritis Experimental/inmunología , Encefalomielitis Autoinmune Experimental/inmunología , Animales , Anticuerpos Monoclonales/genética , Anticuerpos Monoclonales/inmunología , Artritis Experimental/genética , Colágeno Tipo II/inmunología , Modelos Animales de Enfermedad , Encefalomielitis Autoinmune Experimental/genética , Femenino , Predisposición Genética a la Enfermedad , Glucosa-6-Fosfato Isomerasa/genética , Glucosa-6-Fosfato Isomerasa/inmunología , Masculino , Ratones , Organismos Libres de Patógenos Específicos , Estadísticas no ParamétricasRESUMEN
In vivo studies have suggested the immunomodulatory properties of Septilin, an herbal preparation. This drug is being used against various types of inflammatory disorders. However, the mechanism of action of Septilin in the modulation of inflammation is not explored using suitable in vitro models. Hence, we decided to study the modulatory role of Septilin in lipopolysaccharide (LPS) mediated signaling in macrophage and monocyte cells. It was observed from the present study that by employing tumor necrosis factor α (TNF-α) bioassay and reverse transcription-polymerase chain reaction (RT-PCR), Septilin inhibited TNF-α production in LPS (1 µg/mL) stimulated RAW 264.7 cells (p < 0.05). 80% inhibition of TNF-α was observed even at 2.5% Septilin. Septilin at all the concentrations tested could also significantly block the LPS mediated nitric oxide (NO) production (p < 0.01) and expression of inducible NO synthase (iNOS) gene. LPS mediated interleukin 6 (IL-6) and IL-8 production was also blocked by Septilin at the concentrations tested. This herbal preparation could also inhibit cycloxygenase 2 (COX-2) activity and suppression of COX-2 and phosphodiesterase 4 B (PDE4B) mRNA expression in a concentration dependent manner. Taken together, these findings from the present in vitro study suggest the anti-inflammatory and immunomodulatory properties of Septilin.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Activación de Macrófagos/efectos de los fármacos , Macrófagos/efectos de los fármacos , Monocitos/efectos de los fármacos , Extractos Vegetales/farmacología , Animales , Técnicas de Cultivo de Célula , Línea Celular , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/inmunología , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 4/genética , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 4/inmunología , Ciclooxigenasa 2/genética , Ciclooxigenasa 2/inmunología , Ensayo de Inmunoadsorción Enzimática , Interleucina-6/inmunología , Interleucina-8/inmunología , Lipopolisacáridos/farmacología , Macrófagos/inmunología , Ratones , Monocitos/inmunología , Óxido Nítrico/antagonistas & inhibidores , Óxido Nítrico/inmunología , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Factor de Necrosis Tumoral alfa/genética , Factor de Necrosis Tumoral alfa/inmunologíaRESUMEN
OBJECTIVES: To assess the human complement inhibitor C4b-binding protein (C4BP) for treatment of arthritis. METHODS: We have used two mouse models of rheumatoid arthritis (RA) to assess the therapeutic effect of C4BP on different phases of arthritis, the collagen antibody-induced arthritis (CAIA), an acute antibody-induced disease and the collagen-induced arthritis (CIA), which carries the full complexity of arthritis. RESULTS: Purified human C4BP injected intraperitoneally alleviated CAIA significantly in a manner similar to cobra venom factor that depletes complement due to massive activation. Furthermore, C4BP was injected before and after the disease development into CIA mice. In the former case, the disease onset was delayed and in the latter, the severity of the disease was reduced in animals treated with C4BP. However, C4BP did not affect the anti-CII antibody synthesis. C4BP present in mouse sera decreased activity of the classical but not the alternative pathway of the complement system when these were assessed in a fluid phase. However, C4BP was efficiently inhibiting the alternative pathway when present on the activating surface. Taken together, the disease ameliorating effect of C4BP appears to be related to inhibition of both pathways of complement. CONCLUSIONS: Although human C4BP was cleared relatively fast from the circulation and was only moderately affecting complement activity, its effect on the disease severity was substantial, suggesting that minor alterations in complement activity can have significant therapeutic value in RA.
Asunto(s)
Artritis Experimental/tratamiento farmacológico , Proteína de Unión al Complemento C4b/uso terapéutico , Animales , Anticuerpos Monoclonales , Artritis Experimental/inmunología , Artritis Experimental/prevención & control , Artritis Reumatoide/tratamiento farmacológico , Artritis Reumatoide/inmunología , Artritis Reumatoide/prevención & control , Colágeno/inmunología , Complemento C4b/inmunología , Vía Alternativa del Complemento/efectos de los fármacos , Vía Clásica del Complemento/efectos de los fármacos , Humanos , Masculino , Ratones , Ratones MutantesRESUMEN
OBJECTIVES: Autoimmune diseases such as rheumatoid arthritis (RA) and multiple sclerosis (MS) affect a relatively large portion of the population, leading to severe disability if left untreated. Even though pharmaceutics targeting the immune system have revolutionised the therapy of these diseases, there is still a need for novel, more effective therapeutic substances. One such substance is the new chemical entity 9-chloro-2,3 dimethyl-6-(N,N-dimthylamino-2-oxoethyl)-6H-indolo [2,3-b] quionoxaline, Rabeximod, currently being investigated for efficiency in treatment of human RA. In this study we aimed to evaluate Rabeximod as a treatment for autoimmune diseases, using animal models. METHODS: In the present investigation we have evaluated Rabeximod as a treatment for autoimmune diseases using mouse models of RA and MS, ie, collagen-induced arthritis, collagen antibody induced arthritis and experimental autoimmune encephalomyelitis. RESULTS: Rabeximod efficiently prevented arthritis and encephalomyelitis in mice. In addition, this effect correlated to the timepoint when cells migrate into the joints. CONCLUSIONS: We conclude that Rabeximod reduces disease severity in animal models of autoimmunity and should be considered as a new therapeutic substance for MS and RA.
Asunto(s)
Enfermedades Autoinmunes/tratamiento farmacológico , Inmunosupresores/uso terapéutico , Indoles/uso terapéutico , Quinoxalinas/uso terapéutico , Animales , Artritis Reumatoide/tratamiento farmacológico , Colágeno , Citocinas/análisis , Modelos Animales de Enfermedad , Ratones , Ratones Mutantes , Esclerosis Múltiple/tratamiento farmacológico , Ratas , Especies Reactivas de Oxígeno/análisis , Especies Reactivas de Oxígeno/metabolismo , Resultado del TratamientoRESUMEN
Identification of genes controlling complex diseases has proven to be difficult; however, animal models may pave the way to determine how low penetrant genes interact to promote disease development. We have dissected the Cia5/Eae3 susceptibility locus on mouse chromosome 3 previously identified to control disease in experimental models of multiple sclerosis and rheumatoid arthritis. Congenic strains showed significant but small effects on severity of both diseases. To improve the penetrance, we have now used a new strategy that defines the genetic interactions. The QTL interacted with another locus on chromosome 15 and a partial advanced intercross breeding of the two congenic strains for eight generations accumulated enough statistical power to identify interactions with several loci on chromosome 15. Thereby, three separate loci within the original QTL could be identified; Cia5 affected the onset of arthritis by an additive interaction with Cia31 on chromosome 15, whereas the Cia21 and Cia22 affected severity during the chronic phase of the disease through an epistatic interaction with Cia32 on chromosome 15. The definition of genetic interactions was a prerequisite to dissect the Cia5 QTL and we suggest the partial advanced intercross strategy to be helpful also for dissecting other QTL controlling complex phenotypes.
Asunto(s)
Artritis/genética , Epistasis Genética , Predisposición Genética a la Enfermedad , Sitios de Carácter Cuantitativo , Animales , Cruzamientos Genéticos , Femenino , Marcadores Genéticos , Ratones , Mapeo Físico de Cromosoma , Factores de TiempoRESUMEN
OBJECTIVE: To investigate the mode of action of methotrexate (MTX) in different types of models for rheumatoid arthritis (RA) and multiple sclerosis (MS). METHODS: Models for RA and MS were selected known to have different pathogenesis--that is, fibroblast induced arthritis in SCID mice, collagen induced arthritis (CIA), anticollagen II antibody induced arthritis (CAIA), and experimental autoimmune encephalomyelitis (EAE) in (Balb/c x B10.Q)F1 and B10.Q mice, and Pristane induced arthritis in DA rats (PIA). The MTX treatment was started 1 day after the onset of disease and continued for 14 days to compare effects on the different models. RESULTS: All models known to be critically dependent on T cell activation (CIA, PIA, and EAE) were effectively down regulated by titrated doses of MTX. In contrast, no effects were seen on fibroblast induced arthritis or CAIA. No effects were seen on the levels of anticollagen II antibodies in the CIA experiment. CONCLUSION: The data show that MTX has strong ameliorative effect on both classical models of RA, like CIA and PIA, but also on a model for MS, EAE. It also suggests that MTX operates only in diseases which are preceded by, and dependent on, T cell activation. A comparison of CAIA and CIA suggested that MTX operates independently of arthritogenic antibodies. These results demonstrate that different animal models reflect the complexity of the corresponding human diseases and suggest that several models should be used for effective screening of new therapeutic agents.
Asunto(s)
Antirreumáticos/uso terapéutico , Artritis Experimental/tratamiento farmacológico , Artritis Reumatoide/tratamiento farmacológico , Encefalomielitis Autoinmune Experimental/tratamiento farmacológico , Metotrexato/uso terapéutico , Animales , Artritis Experimental/etiología , Artritis Experimental/patología , Artritis Reumatoide/etiología , Artritis Reumatoide/patología , Autoanticuerpos/inmunología , Enfermedades Autoinmunes/tratamiento farmacológico , Colágeno Tipo II/inmunología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Encefalomielitis Autoinmune Experimental/patología , Femenino , Fibroblastos/inmunología , Inmunosupresores/uso terapéutico , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratones SCIDRESUMEN
IL-10 is a pleiotropic cytokine with stimulatory and inhibitory properties, and is thought to have a protective role in rheumatoid arthritis and collagen-induced arthritis (CIA). In this study, we investigated how IL-10 deficiency affects CIA and anti-collagen type II (CII) Ab-transferred arthritis in C57BL/10.Q (B10.Q) mice. The B10.Q.IL-10(-/-) mice had an 8-cM 129/Ola fragment around the IL-10 gene. The mice were treated with antibiotics, appeared healthy, and had no colitis. T cells from IL-10(-/-) mice expressed similar levels of IFN-gamma, IL-2, and IL-4 after mitogen stimulation; however, macrophages showed a reduced TNF-alpha production compared with IL-10(+/-) littermates. IL-10(-/-) mice had an increased incidence, and a more severe CIA disease than the IL-10(+/-) littermates. To study the role of IL-10 in T cell tolerance, IL-10(-/-) were crossed into mice carrying the immunodominant epitope, CII(256-270), in cartilage (MMC) or in skin (TSC). Both IL-10(-/-) and IL-10(+/-) MMC and TSC mice were completely tolerized against CIA, indicating that lack of IL-10 in this context did not break tolerance. To investigate whether IL-10 was important in the effector phase of CIA, arthritis was induced with anti-CII Abs. Surprisingly, IL-10(-/-) were less susceptible to Ab-transferred arthritis, as only 30% showed signs of disease compared with 90% of the littermates. Therefore, IL-10 seemed to have a protective role in CIA, but seemed to exacerbate the arthritogenicity of anti-CII Abs. These data emphasize the importance of studying IL-10 in a defined genetic context in vivo, to understand its role in a complex disease like arthritis.
Asunto(s)
Anticuerpos Monoclonales/toxicidad , Artritis Experimental/inmunología , Artritis/etiología , Enfermedades Autoinmunes/inmunología , Colágeno Tipo II/inmunología , Interleucina-10/fisiología , Animales , Anticuerpos Monoclonales/inmunología , Artritis/inducido químicamente , Artritis/inmunología , Artritis Experimental/genética , Enfermedades Autoinmunes/genética , Colitis/etiología , Colitis/inmunología , Citocinas/biosíntesis , Modelos Animales de Enfermedad , Genotipo , Tolerancia Inmunológica/inmunología , Inmunización , Inmunización Pasiva , Epítopos Inmunodominantes/genética , Epítopos Inmunodominantes/inmunología , Interleucina-10/deficiencia , Interleucina-10/genética , Macrófagos/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Ratones Transgénicos , Organismos Libres de Patógenos Específicos , Factor de Necrosis Tumoral alfa/metabolismoRESUMEN
Approximately 25% of mature T cells possess two distinct cytoplasmic T cell receptor (TCR) alpha-chains, due to productive gene rearrangements of both alleles. Expression of two different alpha-chains at the cell surface is a potential risk factor for development of autoimmunity. However, it has been difficult to determine the frequency of peripheral T cells with two different alpha-chains at the surface. Our new approach is based on comparing by flow cytometry the percentage of cells that express a given Valpha-chain between wild-type mice and mice that are hemizygous for a disrupted Tcra locus (Tcra+/-) and consequently unable to express two rearranged Tcra genes. We consistently found that approximately 8% of total peripheral T cells express two surface alpha-chains. The importance of dual alpha-T cells in autoimmunity was examined in a mouse model for rheumatoid arthritis, namely collagen-induced arthritis (CIA). No significant difference was observed between Tcra+/- mice and wild-type littermates, considering arthritis incidence, day of disease onset, and maximum arthritic score. We therefore conclude that there is incomplete phenotypic allelic exclusion in TCRalpha, and that the presence of a significant number of potentially multireactive T cells does not increase the susceptibility to develop autoimmune arthritis.
Asunto(s)
Autoinmunidad/inmunología , Receptores de Antígenos de Linfocitos T alfa-beta/inmunología , Linfocitos T/inmunología , Animales , Artritis/inmunología , Enfermedades Autoinmunes/inmunología , Ratones , Ratones NoqueadosRESUMEN
To improve the immune potential of porin (a pore-forming protein of Salmonella sp.), different immunopotentiators such as Freund's complete adjuvant (FCA), lipopolysaccharide (LPS) and polyoxydonium (PO) were evaluated by studying the nature of the protective immune response induced against murine Salmonellosis. The nontoxic, synthetic heteropolymer polyoxydonium was as good as LPS at inducing antiporin immunoglobulin G (IgG) antibodies and protective immunity. Analysis of the antiporin IgG subclass pattern revealed a preferential increase in a particular subclass based on the immunopotentiator used. Porin, alone or emulsified in FCA, elicited predominantly antiporin IgG1 antibodies, whereas LPS preferentially evoked antiporin IgG2a, IgG2b and IgG3 antibodies. Polyoxydonium induced a clear shift towards antiporin IgG2b antibodies. The significance of these antiporin IgG subclass antibodies in protection against murine Salmonellosis was studied by passive immunization and by analysing the infected mouse sera.
Asunto(s)
Adyuvantes Inmunológicos , Anticuerpos Antibacterianos/inmunología , Lipopolisacáridos/inmunología , Porinas/inmunología , Infecciones por Salmonella/prevención & control , Animales , Anticuerpos Antibacterianos/clasificación , Modelos Animales de Enfermedad , Femenino , Adyuvante de Freund/inmunología , Hipersensibilidad Tardía , Inmunización Pasiva , Inmunoglobulina G/clasificación , Inmunoglobulina G/inmunología , Inmunoglobulina M/inmunología , Masculino , Ratones , Ratones Endogámicos BALB C , Compuestos Orgánicos , Infecciones por Salmonella/inmunología , Salmonella typhimurium/inmunologíaRESUMEN
We have earlier demonstrated a significant role for IL-12 in the regression of a rat histiocytic tumor, AK-5. In order to analyze further the antitumor immunity induced by interleukin (IL)-12, we have established IL-12-secreting tumor cell clones by gene transfection. Significant enhancement in the lytic potential of splenocytes by the culture supernatants containing IL-12 demonstrated retention of biological activity by the tumor-cell-derived cytokine. Athymic nude mice transplanted subcutaneously with tumor cells engineered to secret IL-12 showed a significant reduction in tumor size, with enhanced antibody-dependent cellular cytotoxicity. Analysis of the serum samples from animals injected with the IL-12 gene-transfected AK-5 cells on different days revealed a significant increase in circulatory IL-12, interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha and antitumor antibodies, all of which contributed to the reduction in tumor mass. The enhanced proliferative capacity of splenocytes from these animals indicated the presence of highly activated immune cells in vivo. Similarly, intraperitoneal transplantation of IL-12 gene-transfected tumor cells in syngeneic Wistar rats induced a significant increase in cellular cytotoxicity, with a concomitant reduction in circulatory IL-12 (p40) protein. Administration of antibodies to IL-12 and IFN-gamma reduced the expression of the costimulatory molecules B7.1 and B7.2 and the cytolytic effectors granzyme B and Fas-L, suggesting their involvement in IFN-gamma-dependent antitumor immune response induced by IL-12. The present study thus demonstrates that IL-12 gene therapy could be among the promising approaches for an effective cancer therapy.
Asunto(s)
Terapia Genética , Histiocitoma Fibroso Benigno/inmunología , Histiocitoma Fibroso Benigno/terapia , Interleucina-12/genética , Animales , Anticuerpos Antineoplásicos/biosíntesis , Antígeno B7-1/metabolismo , Vacunas contra el Cáncer , Concanavalina A/farmacología , Citocinas/metabolismo , Citotoxicidad Inmunológica , Citometría de Flujo , Marcación de Gen , Histiocitoma Fibroso Benigno/genética , Inmunoterapia , Ratones , Ratones Desnudos , Trasplante de Neoplasias , Ratas , Ratas Wistar , Bazo/metabolismo , Factores de Tiempo , Transfección , Células Tumorales Cultivadas , Regulación hacia ArribaRESUMEN
The nature of immune memory induced by a rat histiocytoma, AK-5, in syngeneic hosts was studied. AK-5 tumor when transplanted intraperitoneally (i.p.) into naive animals grows as ascites and is 100% fatal. However, spontaneous regression of AK-5 tumor was observed in 60% of animals upon s.c. transplantation. Interestingly, all the tumor-rejected animals (immune) were found to resist further i.p. challenges with AK-5 cells. The immunity thus developed is specific for AK-5 tumor, since other tumors grow in these animals. In order to understand the tumor-specific immune memory induced after AK-5 tumor transplantation, we have evaluated circulatory-cytokine profiles of i.p. tumor-transplanted naive and immune animals. Our results show an increase in the levels of IL-2, IL-12 and IL-4 in tumor-injected immune animals compared with normal animals, whereas the interferon-gamma levels were totally reversed in these two sets of animals. We also found elevated levels of circulating immune complexes in the sera from AK-5-rechallenged immune animals. We have also evaluated the cytotoxic potential of splenocytes and pure natural killer cells from immune animals rechallenged with AK-5 cells, and have found a significant increase in antibody-dependent cellular cytotoxicity. Similarly, in vitro proliferation of total splenocytes and nylon-wool non-adherent cells from immune animals was much higher compared with the normal animals. The present study thus suggests antigen-independent maintenance of clonal burst size, which could be the form of immune memory induced by AK-5 tumor in the syngeneic host.
Asunto(s)
Citocinas/inmunología , Histiocitoma Fibroso Benigno/inmunología , Memoria Inmunológica , Neoplasias Experimentales/inmunología , Neoplasias Cutáneas/inmunología , Animales , Citotoxicidad Inmunológica , Trasplante de Neoplasias , Ratas , Ratas WistarRESUMEN
Fine-multiple emulsions bearing 6-mercaptopurine (6-MP) in internal aqueous phase were prepared by two step emulsification using sonication technique. It was coated with Concanavalin-A (Con-A) using carbodiimide method to obtain lectin-functionalized multiple emulsions. The Con-A coated multiple emulsion was characterized for antitumour activity on murine leukemia cell line L-1210 in vitro and compared with uncoated multiple emulsion and free drug. An increased uptake and cytotoxicity were observed for Con-A coated multiple emulsion in vitro. The IC50 was decreased upto 4-fold with Con-A coated emulsion. In vivo antitumour activity was seen by recording survival times of mice injected with L-1210 cells i.v. or i.p. The mean survival time was found to increase upon treatment with Con-A coated multiple emulsion. The tumour cell count in the peritoneal cavity was decreased significantly when animal was treated by i.p. route while there was no significant difference when it was treated by i.v. route. The normal peritoneal cells remained unaltered in number and blood parameters were also restored on treatment to tumour bearing mice. The formulation was found to be effective for the treatment of cancer.
Asunto(s)
Antimetabolitos Antineoplásicos/farmacocinética , Concanavalina A , Excipientes , Lectinas , Mercaptopurina/farmacocinética , Animales , Antimetabolitos Antineoplásicos/uso terapéutico , Antimetabolitos Antineoplásicos/toxicidad , Composición de Medicamentos , Emulsiones , Leucemia L1210/tratamiento farmacológico , Leucemia L1210/patología , Mercaptopurina/uso terapéutico , Mercaptopurina/toxicidad , Ratones , Ratones Endogámicos BALB C , Trasplante de Neoplasias , Células Tumorales CultivadasRESUMEN
Differential immune response of syngeneic animals to a rat histiocytoma AK-5 based on the route of transplantation was investigated. Spontaneous regression of subcutaneous tumor was observed in 55-60% of animals. On the other hand, when the tumor cells were injected intraperitoneally, none of the animals survived. Earlier studies from this laboratory indicated upregulation of Th-1-type cytokines, leading to early tumor regression when the tumor was transplanted subcutaneously. Hence we evaluated and compared the circulatory-cytokine profiles in both s.c. and i.p. tumor-injected animals. Our results show an early increase in the p40 subunit of IL-12, prolific increase in IFN-gamma and lower levels of IL-2 in i.p. tumor-injected animals. However, there were no significant differences in the levels of transcripts for these cytokines in either of the groups. Significantly, a lower level of cytotoxicity was observed with splenocytes from i.p. tumor-transplanted animals. Moreover, the cytotoxicity of IL-12-activated but not IL-2-activated NK cells was inhibited by sera (rich in IL-12, p40 subunit) from i.p. tumor-transplanted animals, suggesting the participation of p40 subunit in the regulation of tumor regression. Thus the present study suggests a possible translational regulation of Th-1-type cytokines in AK-5 tumor-host interaction.
Asunto(s)
Histiocitoma Fibroso Benigno/genética , Interferón gamma/genética , Interleucina-12/genética , Adyuvantes Inmunológicos/farmacología , Animales , Anticuerpos Antineoplásicos/sangre , Anticuerpos Antineoplásicos/inmunología , Antineoplásicos/farmacología , Citocinas/sangre , Citocinas/farmacología , Citotoxicidad Inmunológica , Regulación Neoplásica de la Expresión Génica , Histiocitoma Fibroso Benigno/inmunología , Histiocitoma Fibroso Benigno/patología , Sueros Inmunes/farmacología , Interferón gamma/sangre , Interferón gamma/farmacología , Interleucina-12/sangre , Interleucina-12/farmacología , Interleucina-2/sangre , Interleucina-2/genética , Regresión Neoplásica Espontánea , Trasplante de Neoplasias , ARN/análisis , ARN/genética , Ratas , Ratas Wistar , Receptores de Interleucina-2/genética , Proteínas Recombinantes/farmacología , Transcripción Genética , Células Tumorales Cultivadas/efectos de los fármacos , Células Tumorales Cultivadas/inmunología , Células Tumorales Cultivadas/trasplanteRESUMEN
Porins are highly immunogenic outer membrane proteins of Salmonella. Sera from typhoid patients contained a high level of IgG antibodies directed to porins of Salm. typhi. Since porins are highly conserved proteins, anti-porins antibodies both from typhoid patients and healthy normals reacted with porins from several Gram-negative bacteria. Therefore, in order to improve the specificity of detecting Salm. typhi porins-specific antibodies, an inhibition ELISA was developed using enzyme-conjugated MoAbs (MP1 and MPN4) specific to Salm. typhi porins. Sera from typhoid patients with positive haemoculture (16 out of 17) inhibited the binding of MP1 to porins, thus showing a positive test for typhoid, whereas sera from patients with other Gram-negative bacterial infections (n = 7) and from healthy volunteers (66 out of 67) were found to be negative. The sensitivity, specificity, accuracy, positive predictive value and negative predictive value of this assay were 94.1, 98.7, 97.8, 94.1 and 98.7% respectively. The validity of our inhibition ELISA for typhoid was higher than that of the Widal test. The diagnosis of typhoid fever as early as 3 days after the onset of fever, using a single specimen is possible.
Asunto(s)
Anticuerpos Antibacterianos/sangre , Ensayo de Inmunoadsorción Enzimática/métodos , Porinas/inmunología , Salmonella typhi/inmunología , Fiebre Tifoidea/diagnóstico , Adolescente , Adulto , Anciano , Anticuerpos Monoclonales , Especificidad de Anticuerpos , Niño , Preescolar , Ensayo de Inmunoadsorción Enzimática/estadística & datos numéricos , Estudios de Evaluación como Asunto , Humanos , Lactante , Persona de Mediana Edad , Sensibilidad y Especificidad , Fiebre Tifoidea/inmunologíaRESUMEN
Monoclonal antibodies (mAbs) were generated against porins, one of the major outer membrane proteins of Salmonella typhi. Six clones, designated MP1, MP2, MP3 (IgG2ak), MPN4, MPN6 (IgG1k) and MPN5 (IgG2bk) were characterized by enzyme immunoassay (ELISA) for their reactivity to porins from S. typhi, Salmonella paratyphi A, S. paratyphi B, S. paratyphi C, Salmonella choleraesuis, Salmonella enteritidis, Salmonella krefeld, Salmonella panama, Salmonella typhimurium, Escherichia coli B, Shigella flexneri 1b and Pseudomonas aeruginosa. All the clones positive for S. typhi porins showed varying reactivity towards several Salmonella species. However, none of them was positive for porins from other Gram-negative bacteria or for lipopolysaccharide (LPS). The affinity constant of these mAbs, except MPN4, was found to be in the higher range. Dot ELISA revealed that the mAbs recognized porins only in their native form. The results of inhibition ELISA using horseradish peroxidase (HRP)-conjugated MP1 suggest that the clones MP1, MP2, MP3, MPN5 and MPN6 secreted antibodies to identical epitope(s) of a 36-kDa peptide and MPN4 to a different epitope of a 35-kDa peptide. The possible applications of these mAbs were discussed.